AMERICAN ASSOCIATION FOR CANCER RESEARCH 9
through development, approval by regulatory agencies,
and then into the clinic is a complex, multifaceted process
(see Biomedical Research, p. 48). From Aug. 1, 2015, to
July 31, 2016, the FDA approved 18 new medical products
for use in oncology— 13 new anticancer therapeutics,
one new cancer screening test, one new diagnostic test,
two new diagnostic imaging agents, and a new medical
device (see Table 1, p. 10). During this period, the FDA also
approved new uses for 11 previously approved anticancer
Clinical advances such as those listed in Table 1 (see p. 10)
are helping drive down U.S. cancer incidence and death
rates and increase the number of children and adults who
survive a cancer diagnosis (see Table 2, p. 12, for data on
childhood cancer) ( 2-5). In fact, the age-adjusted U.S.
cancer death rate declined by 23 percent from 1991 to
2012, a reduction that translates into 1. 7 million cancer
deaths avoided ( 3). In addition, the U.S. 5-year relative
survival rate for all cancers combined rose from 49 percent
in the mid-1970s to 69 percent in 2011 ( 3).
a diverse array
federal funding organizations; and payers.
advocates and members
of advocacy groups;
THE BIOMEDICAL RESEARCH COMMUNITY:
POWERING PROGRESS TOGETHER
Progress against cancer occurs when individuals in different
segments of the biomedical research community work together.
Further increasing collaboration between stakeholders will
accelerate the pace of lifesaving progress in the future.
The stakeholders in the biomedical research community include:
Adapted from ( 1)